TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect TransMedics Group to post earnings of $0.29 per share and revenue of $123.39 million for the quarter.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $87.72 on Tuesday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business’s fifty day moving average price is $72.84 and its two-hundred day moving average price is $78.63. The stock has a market cap of $2.97 billion, a PE ratio of 93.32 and a beta of 2.14. TransMedics Group has a one year low of $55.00 and a one year high of $177.37.

Analysts Set New Price Targets

TMDX has been the topic of a number of analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.